Publicaciones científicas

/cun/investigacion/publicaciones-cientificas/areaMain/02
  • Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide

    Richardson PG (1), Oriol A (2), Beksac M (3), Liberati AM (4), Galli M (5), Schjesvold F (6), Lindsay J (7), Weisel K (8), White D (9), Facon T (10), San Miguel J (11), Sunami K (12), O'Gorman P (13), Sonneveld P (14), Robak P (15), Semochkin S (16), Schey S (17), Yu X (18), Doerr T (18), Bensmaine A (19), Biyukov T (19), Peluso T (19), Zaki M (18), Anderson K (20), Dimopoulos M (21); OPTIMISMM trial investigators. (1) Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
    (2) Institut Català d'Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain.
    (3) Ankara University, Ankara, Turkey.
    (4) Università degli studi di Perugia, Perugia, Italy.
    (5) Azienda Ospedaliera Papa Giovanni XXIII, Unità Operativa di Ematologia, Bergamo, Italy.
    (6) Oslo Myeloma Center, Oslo University Hospital, Oslo, Norway; K G Jebsen Center for B Cell Malignancies, University of Oslo, Oslo, Norway.
    (7) East Kent Hospitals University NHS Foundation Trust, Kent and Canterbury Hospital, Canterbury, UK.
    (8) Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
    (9) Dalhousie University and Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada.
    (10) University of Lille, Centre Hospitalier Universitaire Lille, Service des Maladies du Sang, Lille, France.
    (11) Clinica Universidad de Navarra, Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain.
    (12) National Hospital Organization Okayama Medical Center, Okayama, Japan.
    (13) Department of Haematology, Mater Misericordiae University Hospital, Dublin, Ireland; Cancer Trials Ireland, School of Medicine and Medical Science, University College Dublin, Dublin, Ireland.
    (14) Erasmus MC Cancer Institute, Rotterdam, Netherlands.
    (15) Medical University of Lodz, Lodz, Poland.
    (16) Pirogov Russian National Research Medical University, Moscow, Russia
    (17) Department of Hematology, King's College London, London, UK.
    (18) Celgene Corporation, Summit, NJ, USA.
    (19) Celgene International, Boudry, Switzerland.
    (20) Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
    (21) National and Kapodistrian University of Athens, Athens, Greece.

    Lancet Oncology 13 de MAYO de 2019

  • Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy

    Perez-Ruiz E (1,2,3,4,5), Minute L (1,2), Otano I (1,2), Alvarez M (1,2), Ochoa MC (1,2,6), Belsue V (1,2), de Andrea C (2,7), Rodriguez-Ruiz ME (1,3), Perez-Gracia JL (2,3,6), Marquez-Rodas I (6,8), Llacer C (9), Alvarez M (5,10,11), de Luque V (5,10), Molina C (1,2), Teijeira A (1,2,6), Berraondo P (12,13,14), Melero I (15,16,17,18,19).

    (1) Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.
    (2) Navarra Institute for Health Research (IDISNA), Pamplona, Spain.
    (3) Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain.
    (4) Department of Oncology, Hospital Costa del Sol, Marbella, Spain.
    (5) Instituto de Investigación Biomédica de Málaga (IBIMA), Hospitales Universitarios Regional y Virgen de la Victoria, Málaga, Spain.
    (6) Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
    (7) Department of Pathology, Clínica Universidad de Navarra, Pamplona, Spain.
    (8) Department of Oncology, Hospital General Universitario Gregorio Marañon, Madrid, Spain.
    (9) Department of Oncology, Hospital Universitario Virgen de la Victoria, Málaga, Spain.
    (10) Laboratorio de Biología Molecular del Cáncer, Centro de Investigaciones Médico-Sanitarias (CIMES), Universidad de Málaga, Málaga, Spain.
    (11) Department of Pathology, Faculty of Medicine, Universidad de Málaga, Málaga, Spain.
    (12) Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.
    (13) Navarra Institute for Health Research (IDISNA), Pamplona, Spain.
    (14) Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
    (15) Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.
    (16) Navarra Institute for Health Research (IDISNA), Pamplona, Spain.
    (17) Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain.
    (18) Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
    (19) Department of Immunology and Immunotherapy, Clínica Universidad de Navarra, Pamplona, Spain.

    Nature 01 de MAYO de 2019

  • Perspectives on Directions and Priorities for Future Preclinical Studies in Regenerative Medicine

    Grigorian Shamagian L (1,2), Madonna R (3,4), Taylor D (5), Climent AM (1,2), Prosper F (6), Bras-Rosario L (7), Bayes-Genis A (2,8), Ferdinandy P (9,10), Fernández-Avilés F (1,2), Izpisua Belmonte JC (11), Fuster V (2,12,13), Bolli R (14).

    (1) From the Hospital Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense, Madrid, Spain (L.G.S., A.M.C., F.F.-A.).
    (2) CIBERCV, ISCIII, Madrid, Spain (L.G.S., A.M.C., A.B.-G., F.F.-A., V.F.).
    (3) Center of Aging Sciences and Translational Medicine (CESI-MeT), Institute of Cardiology, G. d'Annunzio University, Chieti, Italy (R.M.).
    (4) Department of Internal Medicine, the University of Texas Health Science Center at Houston (R.M., ).
    (5) Texas Heart Institute, Houston (D.T.).
    (6) Clinica Universidad de Navarra, Pamplona, Spain (F.P.).
    (7) Cardiology Department, Santa Maria University Hospital (CHLN), Lisbon Academic Medical Centre and Cardiovascular Centre of the University of Lisbon, Faculty of Medicine, Portugal (L.B.-R.).
    (8) Hospital Germans Trias i Pujol, Badalona, Spain (A.B.-G.)
    (9) Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary (P.F.).
    (10) Pharmahungary Group, Szeged, Hungary (P.F.).
    (11) Salk Institute for Biological Studies, La Jolla (J.C.I.B.).
    (12) The Mount Sinai Hospital, New York, NY (V.F.).
    (13) Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain (V.F.).
    (14) University of Louisville (R.B.).

    Circulation Research 15 de MARZO de 2019

  • PEG-PGA enveloped octaarginine-peptide nanocomplexes: An oral peptide delivery strategy

    Niu Z 1, Samaridou E (1), Jaumain E (2), Coëne J (2), Ullio G (2), Shrestha N (3), Garcia J (4), Durán-Lobato M (1), Tovar S (5), Santander-Ortega MJ (6), Lozano MV (6), Arroyo-Jimenez MM (6), Ramos-Membrive R (7), Peñuelas I (7), Mabondzo A (2), Préat V (3), Teixidó M (4), Giralt E (4), Alonso MJ (8).

    (1) Center for Research in Molecular Medicine and Chronic Diseases, IDIS research Institute, Department of Pharmacy and Pharmaceutical Technology, School of Pharmacy, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain.
    (2) Service de Pharmacologie et d'Immunoanalyse, IBITECS, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France.
    (3) Louvain Drug Research Institute, Advanced Drug Delivery and Biomaterials, Université Catholique de Louvain, B-1200 Brussels, Belgium.
    (4) Institute for Research in Biomedicine (IRB Barcelona), Barcelona Institute for Science and Technology (BIST), 08028 Barcelona, Spain.
    (5) Biomedical Research Group, Center for Research in Molecular Medicine and Chronic Diseases, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain.
    (6) Cellular Neuroanatomy, Molecular Chemistry of Central Nervous System Group, Faculty of Pharmacy, University of Castilla-La Mancha, 02071 Albacete, Spain; Regional Centre of Biomedical Research (CRIB), University of Castilla-La Mancha, Albacete, Spain.
    (7) Radiopharmacy Unit, Department of Nuclear Medicine, Clínica Universidad de Navarra, University Clinic of Navarra, 31008 Pamplona, Spain.
    (8) Center for Research in Molecular Medicine and Chronic Diseases, IDIS research Institute, Department of Pharmacy and Pharmaceutical Technology, School of Pharmacy, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain.

    Journal of Controlled Release 06 de MARZO de 2019

  • Personalized re-treatment strategy for uveal melanoma local recurrences after interventional radiotherapy (brachytherapy)

    Tagliaferri L (1), Pagliara MM (2,3), Fionda B (1), Scupola A (1,3), Azario L (4,5), Sammarco MG (2,3), Autorino R (1), Lancellotta V (6), Cammelli S(7), Caputo CG (8), Martinez-Monge R (9), Kovács G (10), Gambacorta MA (1,11), Valentini V (1,11), Blasi MA (2,3).

    (1) U.O.C. Radioterapia Oncologica, Dipartimento di Diagnostica per immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Roma, Italy.
    (2) Istituto di Oftalmologia, Università Cattolica del Sacro Cuore, Roma, Italy.
    (3) UOC di Oncologia Oculare, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Roma, Italy.
    (4) U.O.C. Fisica Sanitaria, Dipartimento di Diagnostica per immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Roma, Italy.
    (5) Istituto di Fisica, Università Cattolica del Sacro Cuore, Roma, Italy.
    (6) University of Perugia and Perugia General Hospital, Radiation Oncology Section, Perugia, Italy.
    (7) Radiation Oncology Center, Department of Experimental, Diagnostic and Specialty Medicine - DIMES, S. Orsola-Malpighi Hospital, University of Bologna, Italy.
    (8) Istituto di Oftalmologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy.
    (9) Clìnica Universidad de Navarra, Navarra, Spain.
    (10) Interdisciplinary Brachytherapy Unit, University of Lübeck - University Hospital S-H, Campus Lübeck, Germany.
    (11) Istituto di Radiologia, Università Cattolica del Sacro Cuore, Roma, Italy.

    Journal of Contemporary Brachytherapy 11 de FEBRERO de 2019

tal vezLE INTERESE

¿QUÉ TECNOLOGÍA UTILIZAMOS?

La Clínica es el hospital privado con mayor dotación tecnológica de España, todo en un único centro.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

NUESTROS
PROFESIONALES

Los profesionales de la Clínica realizan una labor continuada de investigación y formación, siempre en beneficio del paciente.

Imagen profesionales de la Clínica Universidad de Navarra

POR QUÉ VENIR
A LA CLÍNICA

Conozca por qué somos diferentes a otros centros sanitarios. Calidad, rapidez, comodidad y resultados.

Imagen del edificio de la Clínica Universidad de Navarra